Medizin
A novel biomarker for a reliable diagnosis of colorectal cancer based on differentially methylated genomic regions
Ref.-Nr.: 0301-4550-LI
Medizin : Diagnostika
With approximately 600,000 deaths annually colorectal cancer (CRC) is one of the most common cancer types worldwide. Early cancer and pre-cancer (polyps) detection by colonoscopy over the age of 50 until now is the best strategy for disease control and the chance of the cancer to be curable. Epigenetic changes such as DNA methylation has been shown to occur already at early stages of tumor development making such differentially methylated regions (DMRs) highly attractive for biomarker development ...
A novel inhibitor targeting matrix accumulation in cancer
Ref.-Nr.: 0105-5855_1-IKF
Medizin : Therapeutika
Medizin : Tiermodelle
Nukleinsäure-, Protein-, Zell-bezogene Technologien
Cancer remains a major health burden and is the second leading cause of death globally (WHO). The microenvironment of cancer cells plays an important role in disease progression. In particular, the composition of the extracellular matrix regulates angiogenesis, cell proliferation, differentiation, cell survival and apoptosis. Dysregulation and accumulation of the extracellular matrix promotes cellular transformation and metastasis leading to cancer progression. A better understanding of the role ...
Weiterlesen … A novel inhibitor targeting matrix accumulation in cancer
Application of novel channelrhodopsins: molecular engineering, site-specific opsin targeting, discovery of new variants and the advancement in optogenetic devise development
Ref.-Nr.: 0601-4259-MG
Prozesse und Methoden (inkl. Screening) : Lebens-Wissenschaften (inkl. Screening)
Medizin : Therapeutika
Forschungs-Reagenzien : Andere
Nukleinsäure-, Protein-, Zell-bezogene Technologien : Zellen (bezogen)
The development of the cation channel channelrhodopsin-2 (ChR2) from Chlamydomonas reinhardtii by Prof. Ernst Bamberg and his colleagues and its application to light-induced modulation of neurons paved the way for the field of optogenetics.
Over time the light-gated cation channel channelrhodopsin-2 (ChR2) has become an indispensable tool in neuroscience. Based on the pioneering work on ChR2 new variants have emerged, differing in their spectrum of light absorption, their kinetic ...
Biosynthetic production of Paclitaxel
Ref.-Nr.: 0402-6534-MG
Medizin : Therapeutika
The diterpenoid paclitaxel (taxol) is a chemotherapy medication widely used as a first-line treatment against several types of solid cancers. However, adequate supply has remained a major challenge. Extraction of paclitaxel from natural sources is limited, while the chemical synthesis is complex and economically unfavourable. Currently paclitaxel is mainly produced by microbial fermentation or in plant cell cultures with low overall yields. Ideally, paclitaxel production is reconstructed in a ...
Bottom-up assembly of synthetic extracellular vesicles for biomedical applications
Ref.-Nr.: 0105-5888-IKF
Prozesse und Methoden (inkl. Screening) : Lebens-Wissenschaften (inkl. Screening)
Prozesse und Methoden (inkl. Screening) : Produktion
Medizin : Therapeutika
Nukleinsäure-, Protein-, Zell-bezogene Technologien : Protein (bezogen)
Natural extracellular vesicles (EVs) are lipid vesicles that carry a plethora of biologically active molecules including soluble and membrane proteins, nucleic acids and metabolites. They have recently been recognized as a promising cell-free alternative to cell transplantation or as a novel therapeutic tool in various diseases. Many in vitro and in vivo studies have shown beneficial effects of EVs from different cell types in diseases ranging from cardiovascular conditions to ...
Weiterlesen … Bottom-up assembly of synthetic extracellular vesicles for biomedical applications
Broad-spectrum vector-based antiviral and potential live vaccine
Ref.-Nr.: 1402-5459-LC
Medizin
Nukleinsäure-, Protein-, Zell-bezogene Technologien
Our scientists developed a vector-based high tolerable and efficient antiviral (plasmid-derived defective interfering particles) to support IAV pandemic preparedness. The DIP also shows a broad-spectrum antiviral activity against other respiratory viruses, e.g. RSV and SARS-CoV-2 and is Intended for intranasal administration (droplet spray) for human use. A state-of-the-art, high-yield production process in a GMP-ready controlled and sterile environment in animal cell culture.
Weiterlesen … Broad-spectrum vector-based antiviral and potential live vaccine
Compounds modulating frameshifting efficiency for antiviral therapy against HIV-1, SARS-CoV-2 and alphaviruses
Ref.-Nr.: 0707-5639-MG
Medizin : Therapeutika
Medizin : Vakzine
Many viruses use programmed ribosome frameshifting (FS) to increase genome-coding capacity and to regulate the stoichiometric ratio between viral proteins. Among them are human-pathogenic viruses HIV-1, SARS-CoV-2 and alphaviruses such as Semliki Forest virus (SFV). Synthesis of two major HIV-1 genes, gag and pol, requires –1FS. The ratio between Gag and Gag-Pol is crucial for virus propagation and its dysregulation is detrimental for replication, particle formation and infectivity of HIV-1. ...
Dual Inhibition of plexin-B1 and plexin-B2
Ref.-Nr.: 0603-5770-IKF
Medizin : Therapeutika
A novel molecular target of the semaphorin-plexin system to develop treatment options for cancer and for osteoporosis.
f-Chrimson and vf-Chrimson, two ultrafast variants of the red-light activated channelrhodopsin Chrimson
Ref.-Nr.: 0601-5208-MG
Prozesse und Methoden (inkl. Screening) : Lebens-Wissenschaften (inkl. Screening)
Medizin : Therapeutika
Forschungs-Reagenzien : Andere
Nukleinsäure-, Protein-, Zell-bezogene Technologien : Zellen (bezogen)
The development of the cation channel channelrhodopsin-2 (ChR2) from Chlamydomonas reinhardtii by Prof. Ernst Bamberg and his colleagues, and its application to light-induced modulation of neurons paved the way for the field of optogenetics.
Over time the light-gated cation channel channelrhodopsin-2 (ChR2) has become an indispensable tool in neuroscience. Based on the pioneering work on ChR2 new variants have emerged, differing in their spectrum of light absorption, their kinetic ...
FFA2 (GPR43) and FFA3 (GPR41) as novel targets for antidiabetic therapies
Ref.-Nr.: 0603-4987-IKF
Medizin : Therapeutika
Medizin : Tiermodelle
Nukleinsäure-, Protein-, Zell-bezogene Technologien : Protein (bezogen)
A double KO, a conditional KO as well as single KO mouse models for FFA2 and FFA3 (free fatty acid receptors 2 and 3), novel targets for diabetes therapies.
Weiterlesen … FFA2 (GPR43) and FFA3 (GPR41) as novel targets for antidiabetic therapies
Genome-Editing-Technologies - Cas9 double mutant with improved specificity compared to wild-type
Ref.-Nr.: 0306-5787-LI
Prozesse und Methoden (inkl. Screening)
Medizin
Forschungs-Reagenzien
Nukleinsäure-, Protein-, Zell-bezogene Technologien
The RNA-programmable DNA-endonuclease Cas9 is widely used for genome engineering, where a high degree of specificity is required. Though this is a mechanism well controlled by canonical base-pairing, there is evidence that Cas9 does accept mismatches under certain circumstances.
This might be seen as a threat to precision needed in genome engineering at least in environments where such high precision is ultimately needed and acceptance of mismatches needs to be avoided, e.g.: cellular gene ...
Genome-Editing-Technologies - Single compound or compound mix dramatically improve Homology-Directed-Repair (HDR)
Ref.-Nr.: 1306-5734-LI & 1306-5288-LI
Prozesse und Methoden (inkl. Screening)
Medizin
Forschungs-Reagenzien
Nukleinsäure-, Protein-, Zell-bezogene Technologien
Precise genome editing demands for homology-directed repair (HDR) by aiming to introduce a new double stranded DNA substituting for a homologous sequence but partially defect one. This substrate dependent reaction does compete with direct non-homologous end joining (NHEJ) of the double strand breaks. NHEJ is error-prone and is therefor mainly used for gene inactivation.
The rate of NHEJ is directly limiting the rate of HDR. For this reason HDR in vitro does occur on a very low level only and ...
GOLD gRNA - allows robust genome editing regardless of spacer sequence composition by super stable hairpin technology
Ref.-Nr.: 1306-6101-LI
Prozesse und Methoden (inkl. Screening)
Medizin
Forschungs-Reagenzien
Nukleinsäure-, Protein-, Zell-bezogene Technologien
A Cas nuclease such as Cas9 can introduce a DNA double strand break in a sequence target that is complementary to a 20-nt spacer sequence of its bound guide RNA (gRNA) when a protospacer adjacent motif (PAM) is present. The gRNA can be provided as duplex of spacer containing CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA). Or as a single gRNA (sgRNA) where crRNA and tracrRNA are fused by an artificial loop.
Hence a gRNA consists of the target-specific spacer and a constant part typically ...
LITESEC - Light-controlled protein delivery into eukaryotic cells with high spatial and temporal resolution
Ref.-Nr.: 0706-5707-IKF
Prozesse und Methoden (inkl. Screening) : Lebens-Wissenschaften (inkl. Screening)
Medizin : Arzneimittel-Darreichung
Nukleinsäure-, Protein-, Zell-bezogene Technologien : Protein (bezogen)
The LITESEC-T3SS (Light-induced translocation of effectors through sequestration of endogenous components of the T3SS) system represents a novel, fast, specific, and reversible method to control protein secretion into eukaryotic cells, enabling various medicinal and biotechnological applications, such as targeted drug delivery for tumor therapy.
Monoclonal Antibody to Detect Neutrophil Extracellular Traps via a Novel Post Translational Histone Modification
Ref.-Nr.: 0305-5699-LI
Medizin : Therapeutika
Medizin : Diagnostika
Forschungs-Reagenzien : Antikörper
A novel tool to detect and quantify NETs using a molecular feature of NET formation that has never been proposed as a marker for NETs before
Mouse model for mitochondrial diseases
Ref.-Nr.: 1013-4827-IKF
Medizin : Tiermodelle
Forschungs-Reagenzien
A tRNAALA heteroplasmy mouse model to study mitochondrial disorders such as encephalomyophathies, that recapitulates symptoms as observed in human patients with disease-causing mutation in the same mitochondrial gene.
New KDAC assay and selection system
Ref.-Nr.: 0803-5480-IKF
Analytik
Prozesse und Methoden (inkl. Screening) : Lebens-Wissenschaften (inkl. Screening)
Medizin : Diagnostika
Nukleinsäure-, Protein-, Zell-bezogene Technologien : Protein (bezogen)
We present an extremely sensitive, reliable and fast novel Lysine deacetylase (KDAC) assay, which can be performed in a continuous format. This novel KDAC assay is based on Firefly luciferase harboring an acetylation on an essential active site lysine, incorporated by genetic code expansion.
We furthermore offer a bacterial selection system that can help engineer KDACs. The selection system uses a reporter enzyme inactivated by lysine modifications at an essential active site residue, thereby ...
Novel 20S proteasome inhibitors
Ref.-Nr.: 0706-6249-IKF
Medizin
The proteasome is a central component of the protein degradation machinery in eukaryotic cells and plays a role in regulating cell cycle, neoplastic growth and metastasis. Disruption of this degradative process with small molecule inhibitors against one or more catalytic subunits has implications in a number of human diseases such as cancer, inflammation and ischemic stroke and has exposed the proteasome as an important therapeutic target. Three proteasome inhibitors have so far received regulatory ...
Novel biomarker for diagnosis and targeted therapy of Acute Myeloid Leukemia (AML)
Ref.-Nr.: 0204-6248-MG
Medizin : Diagnostika
New biomarker candidates for diagnostic sub-classification of AML patients with elevated expression of mitochondrial proteins and subsequent targeted therapy with BCL-2 inhibitors like venetoclax and/or agents targeting mitochondrial complex I
Weiterlesen … Novel biomarker for diagnosis and targeted therapy of Acute Myeloid Leukemia (AML)
Novel biomarkers and therapeutic indications for PARP1 inhibitors
Ref.-Nr.: 1013-6700-1-IKF
Medizin
HR-defective cancers are a class of malignancies characterized by impaired DNA repair mechanisms, typically resulting from mutations or deficiencies in genes involved in the Homologous Recombination (HR) pathway, such as BRCA1 and BRCA2. These cancers pose significant challenges in treatment due to their inherent resistance to standard therapies.
Poly ADP-ribose Polymerase 1 (PARP1) inhibitors represent a promising targeted therapy class designed to exploit ...
Weiterlesen … Novel biomarkers and therapeutic indications for PARP1 inhibitors
Novel Biomarkers for Ageing and Metabolic Health
Ref.-Nr.: 1013-5354-IKF
Analytik
Medizin : Therapeutika
Medizin : Diagnostika
Forschungs-Reagenzien : Andere
Nukleinsäure-, Protein-, Zell-bezogene Technologien : Zellen (bezogen)
Biomarkers of ageing have long been sought after to help assess the biological age and general health status of individuals. Considerable efforts have been invested to identify such biomarkers, including physiologic readouts, metabolic parameters, glycomic profiles and others. Nevertheless, markers with strong predictive power have remained elusive.
Work in model organisms has identified several conserved signaling pathways that extend life span, such as reduced insulin/IGF signaling and ...
Weiterlesen … Novel Biomarkers for Ageing and Metabolic Health
Novel PDE6δ inhibitors for the treatment of K-Ras mutant pancreatic cancer
Ref.-Nr.: 0803-5326-IKF
Medizin
Pancreatic cancer continues to pose significant challenges in the field of oncology, with dismal survival rates and limited treatment options. Patients diagnosed with this aggressive malignancy often face an uphill battle, with a five-year relative survival rate of just 11%.
Ras proteins are well-known as pivotal regulators of cell growth, proliferation, and differentiation, with their dysfunction implicated ...
Weiterlesen … Novel PDE6δ inhibitors for the treatment of K-Ras mutant pancreatic cancer
Novel PROTACs for the treatment of autoimmune diseases
Ref.-Nr.: 0803-6605-2-IKF
Medizin
Autoimmune diseases affect approximately 5%–8% of the global population, causing immense suffering and posing a significant socioeconomic burden.
Over 80 autoimmune diseases have been identified so far, including Rheumatoid Arthritis, Multiple Sclerosis, and Systemic Erythematosus Lupus.
Current immune-modulatory drugs used in treating autoimmune diseases are non-specific and often ...
Weiterlesen … Novel PROTACs for the treatment of autoimmune diseases
Novel PROTACs for the treatment of cancer
Ref.-Nr.: 0803-6605-1-IKF
Medizin
Cancer stands as the second-leading cause of human death worldwide, following closely behind cardiovascular and cerebrovascular diseases, with a prevalence that continues to rise.
Pancreatic cancer, in particular, continues to challenge the field of oncology with a 5-years survival rate of 11% and limited treatment options. Hematologic malignancies have also seen a steady rise in incident cases since 1990, ...
Novel treatment to restore neurological function in patients with Multiple Sclerosis
Ref.-Nr.: 0707-5835-IKF
Medizin
Multiple sclerosis (MS) is the most common non-traumatic disabling disease among young adults. It affects approximately 2.8 million individuals worldwide, with increasing incidence and prevalence in both developed and developing countries.
The current immunomodulatory treatments for MS primarily address inflammation but fall short in promoting myelin repair and neurological function restoration.
Therefore, ...
Weiterlesen … Novel treatment to restore neurological function in patients with Multiple Sclerosis
Overcoming disease persistence in myeloproliferative neoplasms (MPN) through combinatorial inhibitor treatment
Ref.-Nr.: 0204-5895-MG
Medizin : Therapeutika
The mRNA processing factor YBX1 is a novel target in Myeloproliferative neoplasms (MPNs), which in an combinatorial inhibitor treatment with JAK inhibitors completely overcomes disease persistance.
Suicide gene-armed oncolytic virus for enhanced cancer treatment
Ref.-Nr.: 0204-4297-IKF
Medizin
Cancer stands as the second-leading cause of human death worldwide, following closely behind cardiovascular and cerebrovascular diseases, with a prevalence that continues to rise. In particular, hepatocellular carcinoma is a significant health concern, ranking as the third leading cause of cancer-related deaths, and with a rising incidence rate due to increasing levels of cirrhosis and NAFLD/NASH.
Despite recent advancements in cancer therapies, ...
Weiterlesen … Suicide gene-armed oncolytic virus for enhanced cancer treatment
Ultracompact medical ventilation system
Ref.-Nr.: 0901-6012-WT
Medizin
Sensoren, Geräte und Komponenten
The invention relates to a new, ultracompact non-invasive medical ventilation system. The BIPAP (Biphasic Positive Airway Pressure) ventilation unit, of size and weight of a tennis ball, is easy to handle and allows low-budget mass production. It can be powered by a rechargeable battery-pack – a great advantage in case of mobile use or damaged/unstable infrastructure leading to frequent blackouts. These benefits, ...
Xenorhodopsin - a new inward-directed proton pump for an alternative optogentic approach
Ref.-Nr.: 0601-5295-MG
Prozesse und Methoden (inkl. Screening) : Lebens-Wissenschaften (inkl. Screening)
Medizin : Therapeutika
Forschungs-Reagenzien : Andere
Nukleinsäure-, Protein-, Zell-bezogene Technologien : Zellen (bezogen)
The development of the cation channel channelrhodopsin-2 (ChR2) from Chlamydomonas reinhardtii by Prof. Ernst Bamberg and his colleagues, and its application to light-induced modulation of neurons paved the way for the field of optogenetics.
Over time the light-gated cation channel channelrhodopsin-2 (ChR2) has become an indispensable tool in neuroscience. Based on the pioneering work on ChR2 new variants have emerged, differing in their spectrum of light absorption, their kinetic ...